KRIBIOLISA™ Atezolizumab (TECENTRIQ) ELISA
₹66,000.00
Enzyme Immunoassay for the estimation of Atezolizumab (TECENTRIQ) in serum and plasma.
Key features:
1. Developed using highly specific monoclonal anti-idiotypic antibodies in a sandwich assay format
2. Validated as per international bioassay validation guidelines
3. Recovery: 80-120%
4. Precision CV <10%
Availability: 3 – 4 Weeks | Pack Size: 1 x 96 wells
Powered by Bioz
Description
Background:
Atezolizumab (trade name Tecentriq) is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). In 2015, it was in clinical trials as an immunotherapy for several types of solid tumors. It was under investigation by Genentech/Roche. In April 2016, Roche announced that atezolizumab had been granted fast track status for lung cancer by the FDA. In May 2018, Tecentriq was in combination with Avastin and standard chemotherapy for some patients with lung cancer was granted priority review.
Intended Use:
For Estimation of Atezolizumab (TECENTRIQ) in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.
Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Atezolizumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Atezolizumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Atezolizumab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Atezolizumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!
Additional information
| Species | Human |
|---|---|
| Biomarker Estimation | measures free drug |
| Sample Type | Serum (100 ul), EDTA Plasma (100 ul), Heparin Plasma (100 ul), Citrate Plasma (100 ul) |
| Calibration Range | 20 ng/ml ? 640 ng/ml |
| Sensitivity | 80 ng/ml |
| Detection Method | Colorimetric |
| Specificity | 80% – 120% to Atezolizumab (TECENTRIQ) |
| Cross Reactivity | < 0.5% cross-reactivity observed with related biomarker. |
| Interference | No significant interference observed with available related molecules. |
| Regulatory Status | Research Use Only |
| Research Area | Immune Checkpoints |
| Entez Gene ID | MPDL 3280A Human |
| Alternate Names / Synonyms | Atezolizumab |
| Alternate Drug Brand Names | Tecentriq |
| Drug Bank Accession Number | DB11595 |
| ELISA Type | Direct Sandwich Assay |
| Storage Temperature | Store the unopened product at 2-8 Deg C. Opened products to be stored as per temperatures indicated on the datasheet. |
| Validation | The kit uses a biosimilar research grade standard / calibrator. The standard / calibrator has been validated against WHO/NIBSC standard and/or against commercially sourced innovator drug where available. Please refer to the IFU for more details. |
| Disclaimer | Trade name indicated is for reference purposes only. It does not reflect any licences or patent usage. The tradename is the registered trademark of the respective owners only. |
| Long Name | Protein Based Therapies – Monoclonal Antibody |